Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT07354230
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 210 participants
- Sponsor
- Pirogov Russian National Research Medical University
- Registry
-
NCT07354230
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT07354230. Randomized; no masking; primary purpose treatment. Start 2022-01-11 (actual); primary completion 2024-09-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
- Acronym
- REGATA
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- Rebamipide 100mg
- Intervention (Drug)
- Pantoprazole
- Lead sponsor
- Pirogov Russian National Research Medical University
Record details
- Record id
cardio:ct-nct07354230- Content hash
47d39692591ba62a1b25a3601963c28b089fdda90b99d92817032ee7d8e35623